Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Open-label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients With Advanced or Metastatic Solid Tumors

NCT05076552 is registered in ClinicalTrials.gov with Tachyon Therapeutics, Inc. as lead sponsor.

NCT NCT05076552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05076552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Open-label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Tachyon Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
February 17, 2023
Completion date
July 31, 2025
Enrollment
30 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic solid tumor, solid tumor